Pin1-mediated prolyl isomerization of runx1 affects PU.1 expression in pre-monocytes

Journal of Cellular Physiology

Volumn 229, Issue 4, 2014, Pages 443-452

  Islam, Rabia ^a   Yoon, Won Joon ^a   Woo, Kyung Mi ^a   Baek, Jeong Hwa ^a   Ryoo, Hyun Mo ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; PEPTIDYLPROLYL ISOMERASE PIN1; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOMERIZATION; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 84890514802     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24462     Document Type: Article

References (60)

1. Akiyama H, Misawa T, Ono M, Uchida C, Uchida T. 2011. Prolyl isomerase pin1 protects mice from endotoxin shock. PloS ONE 6:e14656.
2. Bai YC, Srinivasan L, Perkins L, Atchison ML. 2005. Protein acetylation regulates both PU.1 transactivation and Ig kappa 3′ enhancer activity. J Immunol 175:5160-5169.
3. Barberi TJ, Dunkle A, He YW, Racioppi L, Means AR. 2012. The prolyl isomerase Pin1 modulates development of CD8+ cDC in mice. PloS ONE 7:e29808.
4. Carotta S, Dakic A, D'Amico A, Pang SH, Greig KT, Nutt SL, Wu L. 2010. The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. Immunity 32:628-641.
5. Dahl R, Walsh JC, Lancki D, Laslo P, Iyer SR, Singh H, Simon MC. 2003. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol 4:1029-1036.
6. Dakic A, Metcalf D, Di Rago L, Mifsud S, Wu L, Nutt SL. 2005. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med 201:1487-1502.
7. Dakic A, Wu L, Nutt SL. 2007. Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? Trends Immunol 28:108-114.
8. DeKoter RP, Singh H. 2000. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288:1439-1441.
9. Finn G, Lu KP. 2008. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets 8:223-229.
10. Forsberg M, Carlen M, Meletis K, Yeung MS, Barnabe-Heider F, Persson MA, Aarum J, Frisen J. 2010. Efficient reprogramming of adult neural stem cells to monocytes by ectopic expression of a single gene. Proc Natl Acad Sci USA 107:14657-14661.
11. Friedman AD. 2007. Transcriptional control of granulocyte and monocyte development. Oncogene 26:6816-6828.
12. Fujimori F, Takahashi K, Uchida C, Uchida T. 1999. Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest. Biochem Biophys Res Commun 265:658-663.
13. Growney JD, Shigematsu H, Li Z, Lee BH, Adeisperger J, Rowan R, Curley DP, Kutok JL, Akashi K, Williams IR, Speck NA, Gilliland DG. 2005. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106:494-504.
14. Guo H, Friedman AD. 2011. Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J Biol Chem 286:208-215.
15. Guo H, Ma O, Speck NA, Friedman AD. 2012. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis. Blood 119:4408-4418.
16. Himes SR, Cronau S, Mulford C, Hume DA. 2005. The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages. Oncogene 24:5278-5286.
17. Hoogenkamp M, Krysinska H, Ingram R, Huang G, Barlow R, Clarke D, Ebralidze A, Zhang P, Tagoh H, Cockerill PN, Tenen DG, Bonifer C. 2007. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. Mol Cell Biol 27:7425-7438.
18. Hoogenkamp M, Lichtinger M, Krysinska H, Lancrin C, Clarke D, Williamson A, et al. Early chromatin unfolding by RUNX1: a molecular explanation for differential requirements during specification versus maintenance of the hematopoietic gene expression program. Blood 2009; 114:299-309.
19. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z, Koschmieder S, Okuno Y, Dayaram T, Growney JD, Shivdasani RA, Gilliland DG, Speck NA, Nimer SD, Tenen DG. 2008. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 40:51-60.
20. Ichikawa M, Asai T, Chiba S, Kurokawa M, Ogawa S. 2004a. Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle 3:722-724.
21. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Ogawa S, Kurokawa M, Hirai H. 2004b. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10:299-304.
22. Iwasaki H, Akashi K. 2007. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 26:726-740.
23. Jin H, Li L, Xu J, Zhen FH, Zhu L, Liu PP, Zhang MJ, Zhang WQ, Wen ZL. 2012. Runx1 regulates embryonic myeloid fate choice in zebrafish through a negative feedback loop inhibiting Pu.1 expression. Blood 119:5239-5249.
24. Jundt F, Kley K, Anagnostopoulos I, Prosting KS, Greiner A, Mathas S, Scheidereit C, Wirth T, Stein H, Dorken B. 2002. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99:3060-3062.
25. Laribee RN, Klemsz MJ. 2001. Loss of PU.1 expression following inhibition of histone deacetylases. J Immunol 167:5160-5166.
26. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, Gantner BN, Dinner AR, Singh H. 2006. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 126:755-766.
27. Leddin M. 2011. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells (vol 117, pg 2827, 2011). Blood 117:5783.
28. Lee TH, Pastorino L, Lu KP. 2011. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med 13:e21.
29. Li B, Carey M, Workman JL. 2007. The role of chromatin during transcription. Cell 128:707-719.
30. Li YL, Okuno Y, Zhang P, Radomska HS, Chen HM, Iwasaki H, Akashi K, Klemsz MJ, McKercher SR, Maki RA, Tenen DG. 2001. Regulation of the PU.1 gene by distal elements. Blood 98:2958-2965.
31. Lu KP, Finn G, Lee TH, Nicholson LK. 2007. Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol 3:619-629.
32. Lu KP, Suizu F, Zhou XZ, Finn G, Lam P, Wulf G. 2006. Targeting carcinogenesis: A role for the prolyl isomerase Pin1? Mol Carcinog 45:397-402.
33. Lu KP, Zhou XZ. 2007. The prolyl isomerase PI N1: A pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8:904-916.
34. Mak KS, Funnell AP, Pearson RC, Crossley M. 2011. PU.1 and haematopoietic cell fate: Dosage matters. Int J Cell Biol 2011:808524.
35. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, Maki RA. 1996. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. Embo J 15:5647-5658.
36. Metcalf D. 2006. Loss of PU.1: One of the many roads to myeloid leukemia. Cell Cycle 5:673-674.
37. Metcalf D, Dakic A, Mifsud S, Di Rago L, Wu L, Nutt S. 2006. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA 103:1486-1491.
38. Moreau-Gachelin F, Tavitian A, Tambourin P. 1988. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 331:277-280.
39. MoreauGachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G, Briand P, Vainchenker W, Tavitian A. 1996. Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16:2453-2463.
40. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG. 2006. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 107:3330-3338.
41. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG. 2003. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 101:2074.
42. Nerlov C, Graf T. 1998. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 12:2403-2412.
43. Okuda T, vanDeursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
44. Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H, Akashi K, Moreau-Gachelin F, Li Y, Zhang P, Gottgens B, Tenen DG. 2005. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol 25:2832-2845.
45. Putz G, Rosner A, Nuesslein I, Schmitz N, Buchholz F. 2006. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25:929-939.
46. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK, Wagner K, Scheller M, Iwasaki H, Liu CH, Hackanson B, Akashi K, Leutz A, Rothstein TL, Plass C, Tenen DG. 2006. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 38:27-37.
47. Rosenbauer F, Tenen DG. 2007. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 7:105-117.
48. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y, Akashi K, Fiering S, Tenen DG. 2004. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36:624-630.
49. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. 1997. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity 6:437-447.
50. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan XL, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175.
51. Staber PB, Zhang P, Ye M, Welner RS, Nombela-Arrieta C, Bach C, Kerenyi M, Bartholdy BA, Zhang H, Alberich-Jorda M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Orkin SH, Gottgens B, Rosenbauer F, Huang G, Tenen DG. 2013. Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol Cell 49:934-946.
52. Steidl U, Rosenbauer F, Verhaak RGW, Gu XS, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJM, Passegue E, Libermann TA, Delwel R, Tenen DG. 2006. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 38:1269-1277.
53. Takahashi K, Uchida C, Shin RW, Shimazaki K, Uchida T. 2008. Prolyl isomerase, Pin1: New findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease. Cell Mol Life Sci 65:359-375.
54. Tatara Y, Lin YC, Bamba Y, Mori T, Uchida T. 2009. Dipentamethylene thiuram monosulfide is a novel inhibitor of Pin1. Biochem Biophys Res Commun 384:394-398.
55. Tenen DG. 2003. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89-101.
56. Walter MJ, Park JS, Ries RE, Lau SK, McLellan M, Jaeger S, Wilson RK, Mardis ER, Ley TJ. 2005. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proc Natl Acad Sci USA 102:12513-12518.
57. Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD. 2009. Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis 43:30-34.
58. Yeh ES, Means AR. 2007. PIN1, the cell cycle and cancer. Nat Rev Cancer 7:381-388.
59. Yoon WJ, Islam R, Cho YD, Woo KM, Baek JH, Uchida T, Komori T, van Wijnen A, Stein JL, Lian JB, Stein GS, Choi JY, Bae SC, Ryoo HM. 2013. Pin1-mediated Runx2 modification is critical for skeletal development. J Cell Physiol 228:2377-2385.
60. Zhu XH, Zhang H, Qian MX, Zhao XJ, Yang WT, Wang P, Zhang J, Wang KK. 2012. The significance of low PU.1 expression in patients with acute promyelocytic leukemia. J Hematol Oncol 5:22.